Université De Poitiers

Université D'angers

Bioalternatives Sas

Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Centre National De La Recherche Scientifique-cnrs

Effimune

Inserm

Bransten, Marc Michaël

Sylvie Chevalier

Bernard Vanhove

Nicolas Poirier

Caroline Mary

Jean-Claude Lecron

Hughes Gascan

Franck Morel

Katia Boniface

Francois-Xavier Bernard

Hugues Gascan

Caroline Diveau

Hans Yssel

Marc Michaël Bransten

Caroline Diveu

François-Xavier Bernard

Josy-Anne Froger

Yannick Danger

The present invention relates to several biomarkers, including IL-1RA, IFN-γ and GM-CSF, whose expressions at the mRNA level and at the protein level, correlate with chronic pathologies, such as Lyme disease, in particular the late chronic form of Lyme disease. More specifically, the invention provides methods and kits for the diagnosis of such chronic pathologies and for the assessment of a patient's response to a treatment, as well as methods and therapeutic agents for the treatment of such chronic pathologies.

Diagnostic and treatment of chronic pathologies such as Lyme disease

The invention disclosed herein relates to the field of epidermal repair and skin innate immunity. More particularly, the invention concerns the use of a mix of cytokines to inhibit keratinocyte differentiation, activate skin innate immunity, increase the expression of anti-microbial peptides, and improve epidermal repair. In particular, the invention concerns compositions comprising at least IL-17, TNF&#x3b1; and OSM that can be formulated for topical administration for cosmetic or dermatologic use.

Method for increasing the expression of anti-microbial peptides by keratinocytes comprising administering a composition comprising IL-17, TNF-alpha and OSM

The present invention relates to the field of epidermal repair. More particularly, the invention concerns the use of a molecule able to activate a heteromeric receptor comprising OSMR&#x3b2; as a subunit, for the preparation of a composition for activating in vitro and/or in vivo keratinocyte migration and/or the expression of anti-microbial peptides by the keratinocytes. In particular, the invention concerns the use of OSM and/or IL-17 and/or TNF&#x3b1; and/or IL-31, or agonists thereof, for the preparation of cosmetic or dermatologic compositions.

Compositions for enhancing keratinocyte migration and epidermal repair via a receptor containing OSMR&#x3b2; as a subunit, and applications thereof

Growing community of inventors

Angers, France

Sylvie Chevalier